Navigation Links
QED International Associates Announces Changes to the HealthShares(TM) European Medical Products and Devices Index
Date:1/31/2008

NEW YORK, Jan. 31 /PRNewswire/ -- QED International Associates, Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on Monday February 4, 2008, BioMerieux Worldwide (Euronext: BIM) will replace GYRUS GROUP PLC (GYG LN) in the HealthShares(TM) European Medical Products and Devices Index.

Companies that are included in The HealthShares(TM) European Medical Products and Devices Index are headquartered in Europe, quoted on at least one European Stock Exchange and are engaged in the research, development, manufacturing, distribution and/or commercialization of medical devices and/or products for the treatment or amelioration of human disorders and diseases.

About QED International Associates

QED International, based in New York, is a leading financial industry consulting firm specializing in quantitative modeling and the design, development and maintenance of indexes and Exchange Traded Funds. For more information, visit the company's website at http://www.qedinternational.com.


'/>"/>
SOURCE QED International Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mettler-Toledo International Inc. to Host Fourth-Quarter 2007 Earnings Conference Call
2. Philip Morris International Spin-off Should Spur Nations to Take Urgent Action to Reduce Tobacco Use
3. International consortium announces the 1000 Genomes Project
4. Susan G. Komen for the Cure Sharing Grassroots Advocacy Knowledge With International Representatives in Intensive Dallas Training Session
5. Synutra International, Inc. Amends August 2005 Current Report on Form 8-K and Annual Report on Form 10-K for the Fiscal Year Ended March 31, 2007
6. MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP
7. International Isotopes Inc. Names James Mayer as Chief Operating Officer
8. International brain aging expert challenges the existence of Alzheimers as a disease
9. EHE International Supports the American Liver Foundations Efforts at Raising Awareness for Hepatitis
10. QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index
11. International Sports Sciences Associations Ten Best Resolutions for Better Health in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... Experimentation involving human stem cells (HSCs) ... to its potential for revolutionizing human disease treatment. There are multiple HSC platforms ... cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, but what ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... TopConsumerReviews.com recently ... Mobility Scooters . , Mobility Scooters give freedom to people who need help ... Still others may be facing a long period of rehabilitation after an illness or ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... CRANBURY, N.J. , Dec. 5, 2016 /PRNewswire/ ... pharmaceutical company, today presented data from two Phase ... poster sessions at the 58th annual meeting of ... San Diego, California . The two ... patients with acute myeloid leukemia (AML) and T-cell ...
(Date:12/5/2016)... Dec. 5, 2016   Lexicon Pharmaceuticals, Inc. ... from a Phase 2 clinical study of sotagliflozin, a ... collaboration with JDRF, the leading global organization funding type ... Phase 2 clinical trial, which randomized a total of ... once-daily 400 mg dose of sotagliflozin compared to a ...
(Date:12/5/2016)... 5, 2016  Sharn Anesthesia Inc. announced today that ... distribution partner for Salter Labs.  The company also received ... recognition of outstanding sales performance. Salter Labs ... anesthesia care, including the market gold standard ECO 2 ... distributor of the Parker Flex-Tip® Endotracheal Tube, which is ...
Breaking Medicine Technology: